Inactive Instrument

Press Releases Foamix Pharmaceuticals Ltd. Nasdaq

Equities

IL0011334385

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 19	AQ
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	Feb. 29	AQ
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	Feb. 27	AQ
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 21	AQ
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	AQ
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	Jan. 03	AQ
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	Nov. 07	AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	Nov. 01	AQ
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202	23-10-30	AQ
VYNE Therapeutics Announces Private Placement of $88 Million	23-10-30	AQ
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	23-10-30	AQ
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	AQ
VYNE Therapeutics to Attend BIO International Convention	23-05-18	AQ
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update	23-05-11	AQ
University of Dundee : Spinout agrees potential $50 million deal	23-05-03	AQ
VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-05-01	AQ
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	23-05-01	AQ
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis	23-04-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Foamix Pharmaceuticals Ltd. Nasdaq

Equities

IL0011334385

Press Releases

Filters